The effect of one-electron reduced drugs on hepatic aconitase activity and triglycerides level

1. Abdel-aleem S. et al.: Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J. Mol. Cell Cardiol., 29, 789, 1997.10.1006/jmcc.1996.0323Search in Google Scholar

2. Bachur N.R., Gordon S.L., Gee M.V.: A general mechanism for microsomal activation of quinone anticancer agents to free radicals.Cancer Res., 38, 1745, 1978.Search in Google Scholar

3. Bizzi A. et al.: Adriamycin causes hyperlipemia as a consequence of nephrotoxicity. Toxicol. Lett., 18, 291, 1983.10.1016/0378-4274(83)90109-1Search in Google Scholar

4. Brown J.M.: The hypoxic cell: a target for selective cancer therapy- eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res., 59, 5863, 1999.Search in Google Scholar

5. Czuba B. et al.: The effect of thyroxin on hepatic redox equilibrium and lipid metabolism in rats treated with doxorubicin. Curr Issues Pharm Med Sci., 27(4), 220, 2014.10.1515/cipms-2015-0019Search in Google Scholar

6. Dorie M.J., Brown J.M.: Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemotherapy and Pharmacology., 39, 361, 1997.Search in Google Scholar

7. Dudka J. et al.: Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study. Basic Clin. Pharmacol. Toxicol., 97, 74, 2005.10.1111/j.1742-7843.2005.pto_98.xSearch in Google Scholar

8. Hausladen A., Fridovich I.: Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not. J. Biol. Chem., 269, 29405, 1994.Search in Google Scholar

9. Hong B. et al.: Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. Investigational New Drugs., 29, 401, 2011.10.1007/s10637-009-9356-zSearch in Google Scholar

10. Jounaidi Y. and Waxman D.J.: Combination of the bioreductive drug tirapazamine with the chemotherapeutic pro-drug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res., 60, 3761, 2000.Search in Google Scholar

11. Marcu L., Olver I.: Tirapazamine: from bench to clinical trials. Current Clin. Pharmacol., 1, 71, 2006.Search in Google Scholar

12. Minotti G. et al.: Anticancer anthracyclines and the control of iron metabolism: quinine-dependent and independent mechanisms. Methods Enzymol., 378, 340, 2004.10.1016/S0076-6879(04)78025-8Search in Google Scholar

13. Reddy S.B., Williamson S.K.: Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opinion on Investigational Drugs., 18, 77, 2009.Search in Google Scholar

14. Salvatorelli E. et al.: Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. J. Biol. Chem., 281, 10990, 2006.10.1074/jbc.M50834320016423826Search in Google Scholar

15. Salvatorelli E. et al.: Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. II. Amrubicin Shows Metabolic Advantages over Doxorubicin and Epirubicin. JPET., 341, 2474, 2012.10.1124/jpet.111.19026422338034Search in Google Scholar

16. von Pawel J. et al.: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J. Clin. Oncol., 18, 1351, 2000.10.1200/JCO.2000.18.6.135110715308Search in Google Scholar

17. Warren K.E. et al.: Effect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates. Antimicrob. Agents Chemother., 44, 1100, 2000.10.1128/AAC.44.4.1100-1101.20008982410722523Search in Google Scholar

18. Wouters B.G. et al.: Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res., 61, 145, 2001.Search in Google Scholar